Nanox Provides Business Update and Furnishes Certain Preliminary Unaudited Financial Data for Third Quarter Ended September 30, 2026
Key Highlights
- ➤Preliminary Q3 revenue $4.3-$4.4 million, up from $3.4 million year over year
- ➤Cash and deposits $26.0 million, down from $60.0 million at December 31, 2025
- ➤Management says liquidity is insufficient to support operations for at least one year
- ➤Nanox.AI signs Italian distribution agreement with Technologic s.r.l.
- ➤AI and software revenue $1.0 million, up from $0.1 million year over year
PETACH TIKVA, Israel, Oct. 16, 2026 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today provided a brief business update and furnished certain preliminary unaudited financial data for the third quarter ended September 30, 2026. The preliminary figures are estimates based on currently available information, are preliminary and unaudited, and are subject to change upon completion of the Company’s financial close process, final adjustments, management review and other internal procedures, and review by its independent auditors. The Company’s final reported unaudited financial results for the third quarter of 2026 may differ materially from the preliminary figures and will be reported in a subsequent press release at a later date.
Nanox.AI: Nanox AI enters into a distribution agreement with Technologic s.r.l., an Affiliate of Tecnologie Avanzate, to commercialize Nanox.AI’s Bone Solution in Italy. Collaboration leverages Tecnologie Avanzate’s experience, established healthcare industry relationships, and expertise in the Italian market.
Get started
Create a free account to read the full story.